68

Wuhan Healthgen Biotechnology Corp.

688765 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

36.76CNY+2.96 (+8.76%)

Price History

Full chart

Market Stats

Previous Close33.80
Open33.84
Day Range33.46 – 36.84
52-Week Range26.97 – 94.70
Volume13.37M
Market Cap11.12B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.41
Dividend Yield0.00%
50-Day Avg35.67
200-Day Avg51.24

About

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial, recombinant human keratinocyte growth factor, recombinant human fibronectin, recombinant human a-1 antitrypsin, recombinant human lactoferrin, recombinant human epidermal growth factor, and recombinant human fibronectin. In addition, it provides recombinant protein expression, purification process development, and detection methodology services. The company was founded in 2006 and is based in Wuhan, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Daichang Yang
  • Employees278
  • Headquarters268 Shendun 5th Road, Wuhan, China, 430020, China
  • Websitehttps://www.oryzogen.com

Leadership

  • Mr. Daichang YangChairman & GM
  • Mr. Dan YuChief Financial Officer · b. 1977
  • Mr. Zhi Jie QinChief Medical Officer · b. 1964
  • Ms. Xue LiSecretary of the Board · b. 1984
  • Mr. Bo ShiDeputy General Manager · b. 1984
  • Mr. Liangliang DongSenior Director of Scientific Research Projects · b. 1986
  • Mr. Jiquan OuDirector of Scientific Research Projects · b. 1980
  • Ms. Nili WangSenior Manager of Scientific Research Projects · b. 1986

Financials

Income Statement

Currency: CNY2025-12-31
Total Revenue47.86M
Cost of Revenue30.11M
Gross Profit17.75M
Gross Margin37.09%
Operating Expense173.79M
Operating Income-156.03M
Operating Margin-326.01%
EBITDA-83.90M
EBITDA Margin-175.30%
Net Income-157.04M
Net Income Margin-328.11%
R&D92.66M
R&D as % of Total Revenue193.60%
Interest Expense7.56M
Interest Expense % of Total Revenue15.79%

Balance Sheet

Currency: CNY2025-12-31
Total Assets3.70B
Total Liabilities805.00M
Total Equity2.90B
Cash669.44M

Cash Flow

Currency: CNY2025-12-31
Operating Cash Flow-128.32M
Capital Expenditure538.06M
Free Cash Flow-666.38M
Dividends Paid14.50M
FCF to OCF519.31%
Dividend Paid to FCF-2.18%

Key Statistics & Ratios

Market Cap11.12B
Enterprise Value11.23B
Trailing P/E0.00
Forward P/E0.00
Price / Sales208.18
Price / Book3.97
EPS-0.41
Book Value7.95
Revenue (TTM)53.43M
Gross Profit (TTM)16.83M
EBITDA-95.36M
Profit Margin-258.62%
Operating Margin-446.18%
Return on Equity-8.19%
Return on Assets-3.79%
Shares Outstanding357.50M
Shares Float160.64M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%